Mallinckrodt Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MALLINCKRODT, and when can generic versions of MALLINCKRODT drugs launch?
MALLINCKRODT has forty-six approved drugs.
There are thirty-three US patents protecting MALLINCKRODT drugs.
There are one hundred and fifty-nine patent family members on MALLINCKRODT drugs in twenty-two countries and seventy-seven supplementary protection certificates in eight countries.
Summary for Mallinckrodt
International Patents: | 159 |
US Patents: | 33 |
Tradenames: | 39 |
Ingredients: | 29 |
NDAs: | 46 |
Patent Litigation for Mallinckrodt: | See patent lawsuits for Mallinckrodt |
PTAB Cases with Mallinckrodt as patent owner: | See PTAB cases with Mallinckrodt as patent owner |
Drugs and US Patents for Mallinckrodt
Expired US Patents for Mallinckrodt
Paragraph IV (Patent) Challenges for MALLINCKRODT drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 1000 mg/100 mL (10 mg/mL) | ➤ Subscribe | 2011-04-07 |
➤ Subscribe | for Inhalation | 100 ppm and 800 ppm | ➤ Subscribe | 2014-05-20 |
➤ Subscribe | Extended-release Tablets | 7.5 mg/325 mg | ➤ Subscribe | 2014-04-03 |
Premature patent expirations for MALLINCKRODT
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Mallinckrodt Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2904492 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2009064928 | ⤷ Try a Trial |
Japan | 2021155433 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2015127085 | ⤷ Try a Trial |
China | 110501462 | ⤷ Try a Trial |
Japan | 7024013 | ⤷ Try a Trial |
Mexico | 2013007057 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mallinckrodt Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1441735 | SPC/GB08/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
1718641 | 2012/008 | Ireland | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
0786264 | SPC/GB08/019 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801 |
1259550 | 08C0052 | France | ⤷ Try a Trial | PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725 |
0733366 | SPC/GB98/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
2822954 | 1890030-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
2203431 | 2015/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.